Press Releases

 
Press Releases
  Date Title and Summary View
Oct 16, 2017
Company also raises approximately $4M through unrelated business development activities and other sources during September-October BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with le...
Sep 19, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on September 26th, 2017,...
Aug 4, 2017
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017. For the quarter ended June 30, 2017, the Company reported a net loss of $7,...
Jul 21, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and...
Jul 11, 2017
Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malig...
Jun 23, 2017
In preclinical models ARQ 531 demonstrates potent anti-tumor activity in DLBCL BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented ...
Jun 7, 2017
Trial will enroll patients with Overgrowth Diseases driven by the PI3K/AKT1 pathway BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patie...
Jun 3, 2017
83% disease control rate observed in intrahepatic cholangiocarcinoma FGFR2 positive patients BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented ...
May 18, 2017
Data strengthens preclinical profile for ARQ 531 BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress ...
May 17, 2017
Data will be presented from the Phase 1/2 trial of ARQ 087 in intrahepatic cholangiocarcinoma BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that data from the phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with fibroblast growth factor r...
Page:
1
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300